Trv Gp V LLC Purchases New Position in Rapport Therapeutics, Inc. $RAPP

Trv Gp V LLC purchased a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 6,280,525 shares of the company’s stock, valued at approximately $261,709,477,000. Rapport Therapeutics comprises approximately 52.5% of Trv Gp V LLC’s investment portfolio, making the stock its largest holding. Trv Gp V LLC owned 0.13% of Rapport Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in shares of Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock worth $91,077,000 after buying an additional 579,903 shares during the last quarter. BlackRock Inc. bought a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $112,500,000. Vanguard Group Inc. raised its holdings in shares of Rapport Therapeutics by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock valued at $55,151,000 after acquiring an additional 191,219 shares in the last quarter. Johnson & Johnson bought a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $74,360,823,000. Finally, Alliancebernstein L.P. lifted its stake in Rapport Therapeutics by 4.1% in the second quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock worth $13,129,000 after acquiring an additional 45,063 shares during the period.

Wall Street Analyst Weigh In

RAPP has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. BTIG Research restated a “buy” rating and issued a $65.00 price objective on shares of Rapport Therapeutics in a report on Wednesday, August 5th. UBS Group reaffirmed a “strong-buy” rating on shares of Rapport Therapeutics in a research report on Monday. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, HC Wainwright boosted their price target on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $62.86.

Insider Activity

In other Rapport Therapeutics news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares of the company’s stock, valued at approximately $251,535,026.25. This trade represents a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Abraham Ceesay sold 28,958 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the sale, the chief executive officer directly owned 486,108 shares in the company, valued at approximately $23,338,045.08. This represents a 5.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 72,281 shares of company stock worth $3,269,892 in the last three months. 12.48% of the stock is currently owned by insiders.

Rapport Therapeutics Trading Up 1.2%

Shares of RAPP stock opened at $49.01 on Wednesday. Rapport Therapeutics, Inc. has a 12 month low of $13.86 and a 12 month high of $49.50. The stock has a market cap of $2.35 billion, a PE ratio of -16.12 and a beta of 0.97. The company’s fifty day moving average price is $41.39 and its 200-day moving average price is $35.65.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, sell-side analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.